MiMedx Company Top Insiders

MDXG Stock  USD 7.89  0.21  2.59%   
MiMedx's insiders are aggressively selling. The analysis of the overall insider sentiment regarding MiMedx Group suggests that almost all insiders are panicking. MiMedx employs about 837 people. The company is managed by 15 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 55.8 employees per reported executive.

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2025-03-10William Frank Iv HulseDisposed 81446 @ 7.8View
2025-02-28Kimberly Maersk-MollerDisposed 2111 @ 8.4View
2024-03-13William Frank Iv HulseDisposed 20381 @ 7.95View
Monitoring MiMedx's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MiMedx Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

MiMedx's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with MiMedx's future performance. Based on our forecasts, it is anticipated that MiMedx will maintain a workforce of roughly 840 employees by April 2025.
 
Credit Downgrade
 
Yuan Drop
 
Covid

MiMedx Management Team Effectiveness

The company has return on total asset (ROA) of 0.1474 % which means that it generated a profit of $0.1474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2501 %, meaning that it created $0.2501 on every $100 dollars invested by stockholders. MiMedx's management efficiency ratios could be used to measure how well MiMedx manages its routine affairs as well as how well it operates its assets and liabilities. At this time, MiMedx's Return On Assets are most likely to increase slightly in the upcoming years. At this time, MiMedx's Return On Tangible Assets are most likely to increase slightly in the upcoming years. The MiMedx's current Return On Assets is estimated to increase to 0.17, while Non Currrent Assets Other are projected to decrease to roughly 666.9 K.
The current Common Stock Shares Outstanding is estimated to decrease to about 98.3 M. The MiMedx's current Net Loss is estimated to increase to about (31.4 M)

MiMedx Workforce Comparison

MiMedx Group is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 3,184. MiMedx totals roughly 837 in number of employees claiming about 26% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.12.

MiMedx Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MiMedx insiders, such as employees or executives, is commonly permitted as long as it does not rely on MiMedx's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, MiMedx insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
3.6667
11
3
 807,717 
 144,977 
2024-06-01
0.875
7
8
 173,926 
 65,996 
2024-03-01
1.0
6
6
 389,134 
 97,539 
2023-12-01
2.0
2
1
 28,200,249 
 90,000 
2023-06-01
0.5625
9
16
 347,478 
 129,658 
2023-03-01
1.0
6
6
 4,527,771 
 73,670 
2022-06-01
3.0
15
5
 1,798,216 
 141,501 
2021-09-01
0.3333
1
3
 35,212 
 24,141 
2021-06-01
2.25
9
4
 139,815 
 116,081 
2021-03-01
1.3333
8
6
 849,051 
 109,356 
2020-12-01
14.0
14
1
 310,347 
 301.00 
2020-09-01
4.75
19
4
 1,596,902 
 23,476,623 
2020-03-01
0.4
2
5
 30,000 
 35,169 
2019-12-01
1.0
1
1
 49,295 
 292.00 
2019-09-01
0.3333
1
3
 723,154 
 726,565 
2019-06-01
1.75
7
4
 1,163,156 
 151,460 
2019-03-01
0.1538
2
13
 203,305 
 2,029,277 
2018-12-01
0.3636
4
11
 40,000 
 1,466 
2018-03-01
0.3846
5
13
 338,900 
 135,952 
2017-06-01
2.4
12
5
 531,725 
 166,106 
2017-03-01
0.5
5
10
 561,861 
 143,049 
2016-06-01
5.5
11
2
 290,003 
 34,695 
2016-03-01
0.5
4
8
 292,000 
 28,634 
2015-12-01
7.0
7
1
 191,681 
 40,606 
2015-09-01
1.0
3
3
 157,235 
 157,235 
2015-06-01
1.0
9
9
 190,146 
 283,952 
2015-03-01
0.8
8
10
 540,619 
 1,718,736 
2014-12-01
0.4286
3
7
 200,000 
 438,065 
2014-09-01
2.125
17
8
 318,000 
 269,274 
2014-03-01
3.0
9
3
 821,898 
 1,625,000 
2013-12-01
2.0
10
5
 994,750 
 838,173 
2013-09-01
0.6429
9
14
 1,001,898 
 1,275,463 
2013-06-01
5.0
15
3
 166,500 
 100,000 
2012-12-01
1.4444
13
9
 1,735,630 
 2,730,290 
2012-09-01
0.7778
7
9
 716,372 
 1,633,338 
2012-06-01
0.5
1
2
 15,000 
 1,297,000 
2012-03-01
2.8889
26
9
 3,450,783 
 976,912 
2011-09-01
1.25
5
4
 956,250 
 925,000 
2010-12-01
11.0
11
1
 1,651,469 
 280,000 
2010-03-01
7.0
14
2
 2,063,998 
 800,000 
2009-12-01
6.1667
37
6
 3,103,429 
 484,350 
2009-09-01
3.5
35
10
 1,923,622 
 815,815 
2009-06-01
4.0
4
1
 685,000 
 200,000 
2009-03-01
1.3333
4
3
 2,150,000 
 20,000 

MiMedx Notable Stakeholders

A MiMedx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as MiMedx often face trade-offs trying to please all of them. MiMedx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting MiMedx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph CapperCEO DirectorProfile
Robert MDPresident InnovationProfile
Matthew NotarianniHead RelationsProfile
Todd NewtonInterim DirectorProfile
William PhelanVP OfficerProfile
Kim MollerChief OfficerProfile
William IVGeneral OfficerProfile
Douglas CPAChief OfficerProfile
Mark GravesChief Compliance OfficerProfile
Scott TurnerSenior ProcurementProfile
Peter CPAChief OfficerProfile
David MasonChief OfficerProfile
Rohit KashyapPres SurgicalProfile
Kate SurdezChief OfficerProfile
Hilary DixonVice CommunicationsProfile

About MiMedx Management Performance

The success or failure of an entity such as MiMedx Group often depends on how effective the management is. MiMedx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of MiMedx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the MiMedx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.18  0.19 
Return On Capital Employed 0.27  0.28 
Return On Assets 0.16  0.17 
Return On Equity 0.22  0.21 

MiMedx Workforce Analysis

Traditionally, organizations such as MiMedx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare MiMedx within its industry.

MiMedx Manpower Efficiency

Return on MiMedx Manpower

Revenue Per Employee416.8K
Revenue Per Executive23.3M
Net Income Per Employee50.2K
Net Income Per Executive2.8M
Working Capital Per Employee174.8K
Working Capital Per Executive9.8M

Complementary Tools for MiMedx Stock analysis

When running MiMedx's price analysis, check to measure MiMedx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MiMedx is operating at the current time. Most of MiMedx's value examination focuses on studying past and present price action to predict the probability of MiMedx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MiMedx's price. Additionally, you may evaluate how the addition of MiMedx to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules